Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Zovirax 800 mg Dispersible Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dispersible tablet contains 800 mg aciclovir.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Dispersible Tablets.

Product imported from Greece:

White, biconvex, elongated, film-coated tablet, impressed with 'GX CG1' on one face and plain on the other.

4 CLINICAL PARTICULARS

As per PA1077/084/009

5 PHARMACOLOGICAL PROPERTIES

As per PA1077/084/009

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Microcrystalline cellulose Aluminium magnesium silicate Sodium starch glycollate Povidone K30 Magnesium stearate Hypromellose Titanium Dioxide (E171) Polyethylene glycol 400

6.2 Incompatibilities

Polyethylene glycol 8000

There are no special requirements for use on handling of this product.

6.3 Shelf life

The shelf-life expiry date of this product shall be the date shown on the blister and outer package of the product on the market in the country of origin.

6.4 Special precautions for storage

Do not store above 30°C. Keep the blisters in the outer carton in order to protect from light and moisture.

6.5 Nature and contents of container

12 May 2023 CRN00DHZ2 Page 1 of 2

Health Products Regulatory Authority

Each pack contains 35 dispersible tablets. 7 dispersible tablets per child-resistant foil blister.

6.6 Special precautions for disposal

No special requirements.

7 PARALLEL PRODUCT AUTHORISATION HOLDER

IMED Healthcare Ltd, Unit 625 Kilshane Avenue, Northwest Business Park, Ballycoolin, Dublin 15, Ireland.

8 PARALLEL PRODUCT AUTHORISATION NUMBER

PPA1463/199/002

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 12th May 2023

10 DATE OF REVISION OF THE TEXT

12 May 2023 CRN00DHZ2 Page 2 of 2